Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: Risk and corticosteroids in sepsis

Intensive Care Medicine

Volumn 34, Issue 3, 2008, Pages 568-577

  Li, Yan ^a   Cui, Xizhong ^a   Li, Xuemei ^a,b   Solomon, Steven B ^a   Danner, Robert L ^a   Banks, Steven M ^a   Fitz, Yvonne ^a   Annane, Djillali ^c   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Hydrocortisone; Pneumonia; Risk of death; Sepsis; Treatment

Indexed keywords

ACT O VIAL; CEFTRIAXONE; CORTICOSTEROID; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 6; NITRIC OXIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; MALE; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; RISK; SEPSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTEREMIA; CEFTRIAXONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; HYDROCORTISONE; INTUBATION, INTRATRACHEAL; LUNG; MALE; MICE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 43049139533     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0921-7     Document Type: Article

References (35)

1. Knaus WA, Harrell FE, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, Fisher CJ, Soll L (1996) Use of predicted mortality to evaluate the efficacy of anti-cytokine therapy in sepsis: the IL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 24:46-56
2. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C, Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004) Efficacy and safety of the monoclonal anti-tumor necrosis factor F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32:2173-2182
3. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C (2002) Risk and efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197-1205
4. Cui X, Parent C, Macarthur H, Ochs SD, Gerstenberg E, Solomon S, Fitz Y, Danner RL, Banks SM, Natanson C, Salvemini D, Eichacker PQ (2004) Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model. J Appl Physiol 97:1349-1357
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 344:699-709
6. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004) Meta-analysis: the effect of steroids on survival and shock during sepsis depended on dose. Ann Intern Med 141:47-56
7. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic dose hydrocortisone. Crit Care Med 26:645-650
8. Yildiz O, Doganay M, Aygen B, Guven M, Keletimur F, Tutus A (2002) Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 6:251-259
9. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of corticosteroid and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871
10. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU (2005) Hydrocortisone infusion for severe community-acquired pneumonia. A preliminary randomized study. Am J Respir Crit Care Med 171:242-248
11. Sprung CL, Annane D, Briegel J, Keh D, Moreno R, Singer M, Weiss Y, Sorenson F (2007) Corticosteroid therapy of septic shock (CORTICUS). Am J Respir Crit Care Med 175:A507
12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
13. Marrie TJ, Fine MJ, Obrosky DS, Coley C, Singer DE, Kapoor WN (1998) Community-acquired pneumonia due to Escherichia coli. Clin Microbiol Infect 4:717-723
14. Babcock HM, Zack JE, Garrison T, Trovillion E, Kollef MH, Fraser VJ (2003) Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location. Infect Control Hosp Epidemiol 24:853-858
15. http://www.globalrph.com/corticocalc.htm
16. Greisman SE, DuBuy JB, Woodward CL (1979) Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immun 25:538-557
17. Johnston CA, Greisman SE (1984) Endotoxemia induced by antibiotic therapy: a mechanism for adrenal corticosteroid protection in gram-negative sepsis. Trans Assoc Am Physicians 97:172-181
18. Greisman SE (1982) Experimental Gram-negative bacterial sepsis: optimal methylprednisolone requirements for prevention of mortality not preventable by antibiotics alone. Proc Soc Exp Biol Med 170:436-442
19. Freeman BD, Correa R, Karzai W, Natanson C, Patterson M, Banks S, Fitz Y, Danner RL, Wilson L, Eichacker PQ (1996) Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 80:2066-2076
20. Cui X, Moayeri M, Li Y, Li X, Haley M, Fitz Y, Correa-Araujo R, Banks SM, Leppla SH, Eichacker PQ (2004) Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol 286:R699-R709
21. Li Y, Li X, Haley M, Fitz Y, Gerstenberger E, Banks SM, Eichacker PQ, Cui X (2006) DTPA Fe(III) decreases cytokines and hypotension but worsens survival with Escherichia coli sepsis in rats. Intensive Care Med 32:1263-1270
22. Cui X, Li Y, Li X, Laird MW, Subramanian M, Moayeri M, Leppla SH, Fitz Y, Su J, Sherer K, Eichacker PQ (2007) Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 195:572-580
23. Chawla K, Kupfer Y, Goldman I (1999) Hydrocortisone reverses refractory septic shock [abstract]. Crit Care Med [Suppl] 27(1):A33
24. Oppert M, Schindler R, Husung C, Offermann K, Graf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457-2464
25. Briegel J, Jochum M, Gippner-Steppert C, Thiel M (2001) Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 12:S70-S74
26. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H (2003) Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock. A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167:512-520
27. Briegel J, Forst H, Haller M, Schelling G, Kliger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723-731
28. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858-873
29. Mansart A, Bollaert PE, Seguin C, Levy B, Longrois D, Mallie JP (2003) Hemodynamic effects of early versus late glucocorticosteroid administration in experimental septic shock. Shock 19:38-44
30. Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael JC, Gajdos P (1998) Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 46:589-597
31. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y (2004) Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 329:480
32. Hsu FH, Prueksaritanont T, Lee MG, Chiou WL (1987) The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept. J Pharmacokinet Biopharm 15:369-386
33. Samtani MN, Jusko WJ (2005) Stability of dexamethasone sodium phosphate in rat plasma. Int J Pharm 301:262-266
34. Van Dijk H, Bloksma N, Rademaker PM, Schouten WJ, Willers JM (1979) Differential potencies of corticosterone and hydrocortisone in immune and immune-related processes in the mouse. Int J Immmunopharmacol 1:285-292
35. Van Ogtrop ML, Mattie H, Sekh BR, Van Strijen E, Van Furth R (1992) Comparison of antibacterial efficacies of ampicillin and ciprofloxacin against experimental infections with Listeria monocytogenes in hydrocortisone-treated mice. Antimicrob Agents Chemother 36:2375-2380